The relationship of BCR-ABL KD mutations developing in patients compared with those predicted from in vitro treatment with TKIs
| . | In vitro models* . |
|---|---|
| Dasatinib, n=12 | |
| G250E (1) | – |
| V299L (3) | + |
| T315I (1) | + |
| F317L (5) | + |
| L364I (1) | – |
| T495R (1) | – |
| Correlation | 75% of patients; 50% of mutations |
| Nilotinib, n=18 | |
| M244V (1) | – |
| Q252H (1) | + |
| Y253H/F (4) | + |
| E255K (1) | + |
| D276G (1) | – |
| F311I (2) | + |
| T315I (2) | + |
| F359C (1) | + |
| F359V (2) | + |
| H396P (1) | – |
| H396R (1) | – |
| E453K (1) | – |
| Correlation | 72% of patients; 58% of mutations |
| . | In vitro models* . |
|---|---|
| Dasatinib, n=12 | |
| G250E (1) | – |
| V299L (3) | + |
| T315I (1) | + |
| F317L (5) | + |
| L364I (1) | – |
| T495R (1) | – |
| Correlation | 75% of patients; 50% of mutations |
| Nilotinib, n=18 | |
| M244V (1) | – |
| Q252H (1) | + |
| Y253H/F (4) | + |
| E255K (1) | + |
| D276G (1) | – |
| F311I (2) | + |
| T315I (2) | + |
| F359C (1) | + |
| F359V (2) | + |
| H396P (1) | – |
| H396R (1) | – |
| E453K (1) | – |
| Correlation | 72% of patients; 58% of mutations |
Data were summarized from Burgess et al,17 von Bubnoff et al,18 and Bradeen et al.19
– indicates not induced in vitro; +, induced in vitro.